Zacks Investment Research Upgrades Deciphera Pharmaceuticals (DCPH) to “Buy”
Deciphera Pharmaceuticals (NASDAQ:DCPH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday. The brokerage presently has a $35.00 price objective on the stock. Zacks Investment Research‘s target price indicates a potential upside of 19.54% from the stock’s current price.
According to Zacks, “Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib which are in clinical stage. Deciphera Pharmaceuticals, LLC is based in WALTHAM, United States. “
A number of other research firms have also weighed in on DCPH. JMP Securities upped their target price on shares of Deciphera Pharmaceuticals to $65.00 and gave the stock an “outperform” rating in a report on Tuesday, June 19th. B. Riley lowered shares of Deciphera Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $43.00 target price on the stock. in a report on Tuesday, June 19th. SunTrust Banks assumed coverage on shares of Deciphera Pharmaceuticals in a report on Thursday, July 5th. They issued a “buy” rating on the stock. Leerink Swann assumed coverage on shares of Deciphera Pharmaceuticals in a report on Monday, September 24th. They issued an “underperform” rating and a $28.00 target price on the stock. Finally, BidaskClub upgraded shares of Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, September 25th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the stock. Deciphera Pharmaceuticals has a consensus rating of “Buy” and an average price target of $47.55.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its earnings results on Tuesday, August 7th. The company reported ($0.65) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.03. Equities analysts forecast that Deciphera Pharmaceuticals will post -2.61 EPS for the current fiscal year.
Hedge funds have recently modified their holdings of the business. Bank of America Corp DE grew its position in Deciphera Pharmaceuticals by 316.1% in the 2nd quarter. Bank of America Corp DE now owns 2,609 shares of the company’s stock worth $103,000 after purchasing an additional 1,982 shares in the last quarter. SG Americas Securities LLC bought a new stake in Deciphera Pharmaceuticals in the 1st quarter worth about $152,000. New York State Common Retirement Fund grew its position in Deciphera Pharmaceuticals by 37.5% in the 1st quarter. New York State Common Retirement Fund now owns 9,900 shares of the company’s stock worth $198,000 after purchasing an additional 2,700 shares in the last quarter. Trexquant Investment LP bought a new stake in Deciphera Pharmaceuticals in the 2nd quarter worth about $203,000. Finally, Rhumbline Advisers bought a new stake in Deciphera Pharmaceuticals in the 2nd quarter worth about $301,000. 53.53% of the stock is owned by institutional investors and hedge funds.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
Read More: Understanding Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.